|Bid||5.04 x 1100|
|Ask||5.05 x 1800|
|Day's Range||5.01 - 5.18|
|52 Week Range||4.97 - 28.74|
|Beta (3Y Monthly)||0.68|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Diplomat Pharmacy, Inc. New York, May 23, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Diplomat Pharmacy, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
Diplomat Pharmaceuticals (DPLO) delivered earnings and revenue surprises of -371.43% and 8.43%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Flint, Michigan-based company said it had a loss of 19 cents. The results missed Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment ...
The Insider Monkey team has completed processing the quarterly 13F filings for the December quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors endured a torrid quarter, which certainly propelled them to adjust their equity holdings so as to maintain the desired risk profile. As […]
Diplomat Pharmaceuticals (DPLO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Diplomat Pharmacy Inc (NYSE: DPLO ) shares nosedived Feb. 22 after the company reported a delay in its earnings announcement, citing a charge it needs to record related to its pharmacy benefit management ...
Diplomat Pharmacy Inc (NYSE: DPLO ) on Friday reported its previously delayed fourth-quarter earnings miss and concerning guidance, which sent the stock tumbling nearly 14 percent. The Analysts Mizuho ...
Moody's Investors Service commented that Diplomat Pharmacy, Inc.'s ("Diplomat") weakening performance trends, as disclosed in the company's fourth quarter conference call, are credit negative. For additional information please refer to Moody's Issuer Comment on Diplomat Pharmacy, Inc. available on www.moodys.com. This publication does not announce a credit rating action.
On a per-share basis, the Flint, Michigan-based company said it had a loss of $4. Earnings, adjusted for asset impairment costs, came to 14 cents per share. The results missed Wall Street expectations. ...
Moody's Investors Service ("Moody's") downgraded the ratings of Diplomat Pharmacy, Inc. ("Diplomat") including the Corporate Family Rating to B2 from B1, the Probability of Default Rating to B2-PD from B1-PD, the senior secured rating to B2 from B1, and the Speculative Grade Liquidity Rating to SGL-3 from SGL-2. The downgrade of the Corporate Family Rating to B2 from B1 reflects challenging conditions in Diplomat's two major operating segments -- specialty pharmacy and pharmacy benefit management (PBM) -- that will keep debt/EBITDA elevated above the 4.5x threshold that Moody's incorporated in the prior rating of B1.
Investors need to pay close attention to Diplomat Pharmacy (DPLO) stock based on the movements in the options market lately.
said Friday it was postponing the release of its fourth-quarter and full-year 2018 earnings as it and its auditors finalize the level of an impairment charge. The company's outlook of 2018 revenue of $5.5 billion to $5.6 billion and 2018 adjusted EBITDA of $167 million to $170 million remains unchanged, as they are not impacted by the impairment charge, the pharmacy services company said in a release. "The postponement is due primarily to the recent determination by Diplomat and its auditors that the company will need to record a non-cash impairment charge related to its PBM business.
Diplomat Pharmacy Inc said on Friday it would withdraw its full-year forecast and delay its annual and fourth-quarter results after determining that it would need to record a charge related to its pharmacy benefits management (PBM) business. The charge relates to the 2017 acquisitions of National Pharmaceutical Services and LDI and is driven by reduced financial forecasts for the PBM business, Diplomat said. Diplomat bought Missouri-based LDI Integrated Pharmacy Services for $388 million in cash and $80 million in stock, a week after buying NPS, another PBM.
Diplomat Pharmacy Inc said on Friday it would delay its annual and fourth-quarter results after determining that the company will need to record a charge related to its pharmacy benefits management (PBM) business. The charge relates to the 2017 acquisitions of NPS and LDI and is driven by reduced financial forecasts for the PBM business, Diplomat said.